WO2007136782A3 - Kits and methods for evaluating misfolded proteins - Google Patents

Kits and methods for evaluating misfolded proteins Download PDF

Info

Publication number
WO2007136782A3
WO2007136782A3 PCT/US2007/011960 US2007011960W WO2007136782A3 WO 2007136782 A3 WO2007136782 A3 WO 2007136782A3 US 2007011960 W US2007011960 W US 2007011960W WO 2007136782 A3 WO2007136782 A3 WO 2007136782A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
misfolded proteins
kits
evaluating
cell
Prior art date
Application number
PCT/US2007/011960
Other languages
French (fr)
Other versions
WO2007136782A2 (en
Inventor
Eric Anderson
Marisa Dolled-Filhart
Original Assignee
Historx Inc
Eric Anderson
Marisa Dolled-Filhart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Historx Inc, Eric Anderson, Marisa Dolled-Filhart filed Critical Historx Inc
Publication of WO2007136782A2 publication Critical patent/WO2007136782A2/en
Publication of WO2007136782A3 publication Critical patent/WO2007136782A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to methods for identifying misfolded proteins within a cell. In particular, methods are provided for diagnosing a lysosomal storage protein disease by localizing and quantitating one or more disease markers within a cell. Also described are methods for identifying appropriate treatments for patients with lysosomal storage disorders and determining the responsiveness of the patient to various treatment options.
PCT/US2007/011960 2006-05-19 2007-05-21 Kits and methods for evaluating misfolded proteins WO2007136782A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80175306P 2006-05-19 2006-05-19
US60/801,753 2006-05-19

Publications (2)

Publication Number Publication Date
WO2007136782A2 WO2007136782A2 (en) 2007-11-29
WO2007136782A3 true WO2007136782A3 (en) 2008-11-27

Family

ID=38723870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011960 WO2007136782A2 (en) 2006-05-19 2007-05-21 Kits and methods for evaluating misfolded proteins

Country Status (1)

Country Link
WO (1) WO2007136782A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201114909D0 (en) * 2011-08-30 2011-10-12 San Raffaele Centro Fond Biomarkers for lysosomal storage disorders
CN111297902A (en) * 2020-04-14 2020-06-19 南开大学 Application of lysosome in preparation of medicine for treating protein misfolding or processing diseases
AU2022327748A1 (en) * 2021-08-09 2024-02-15 Neuroquest Ltd. Compositions, kits, and methods for detecting preclinical alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759189B1 (en) * 1996-05-17 2004-07-06 Women's And Children's Hopital Early detection of lysosomal storage disorders
US20050191710A1 (en) * 2004-03-01 2005-09-01 Hanrahan John W. Method for labeling a membrane-localized protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759189B1 (en) * 1996-05-17 2004-07-06 Women's And Children's Hopital Early detection of lysosomal storage disorders
US20050191710A1 (en) * 2004-03-01 2005-09-01 Hanrahan John W. Method for labeling a membrane-localized protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARTNER ET AL.: "Mislocalization of deltaF508 CFTR in cystic fibrosis sweat gland", NATURE GENETICS, vol. 1, August 1992 (1992-08-01), pages 321 - 327 *

Also Published As

Publication number Publication date
WO2007136782A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2005114190A3 (en) Methods of identifying biomarkers
WO2008108803A3 (en) Immune cell biosensors and methods of using same
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2007061906A3 (en) Diagnostic and therapeutics for cardiovascular disorders
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
EP1724586A3 (en) Annexin for cancer risk assessment
WO2008021515A3 (en) Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
UA101167C2 (en) Pharmaceutical composition useful for the treatment of ocular disease
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
WO2007137072A3 (en) Assays for diagnosing and evaluating treatment options for fabry disease
WO2011001135A3 (en) Diagnosis and treatment of alzheimer's disease
ATE511645T1 (en) TEST METHOD FOR DETECTING ANTIBODIES AGAINST LYSOSOME ENZYMES
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2010041046A8 (en) Granin proteins as markers of heart disease
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2008054509A3 (en) Methods for assessing cell labeling
WO2007000320A3 (en) Method for diagnosing rheumatic diseases
WO2006084299A3 (en) Method for evaluating the allergen sensitivity of an individual
EP2857522A3 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
WO2007061988A3 (en) Methods for determining notch signaling and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07777169

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07777169

Country of ref document: EP

Kind code of ref document: A2